NKTRNektar Therapeutics
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+23% of shares).
Rangebound, no clear trend. Oversold (RSI 18). Price is −36% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NKTR is trading
Nektar Therapeutics is −25% over the past year while the S&P 500 is +18%: 44 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −36%
vs 200-day average · a clear downtrend
- RSI (14)
- 18
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 59%
Below its 52-week high
Details›
- Last close2026-10-09
- $41.14
- 1 monthS&P 500 +2.7%
- −42%
- 1 yearS&P 500 +18%
- −25%
- 5 yearsS&P 500 +88%
- −83%
- vs 50-day average$66.41
- −38%
- 52-week high
- $100.35
- 52-week low
- $35.12
- Annualised volatility
- 144%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$86K
| Year | Return |
|---|---|
| 2026 (year to date) | −2.7% |
| 2025 | +203% |
| 2024 | +66% |
| 2023 | −75% |
| 2022 | −83% |
| 2021 | −21% |
| 2020 | −21% |
| 2019 | −34% |
| 2018 | −45% |
| 2017 | +387% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +5.2% |
| Feb | 10 | 7 of 10 | +8.7% |
| Mar | 10 | 4 of 10 | −2.1% |
| Apr | 10 | 5 of 10 | +3.7% |
| May | 10 | 2 of 10 | −8.1% |
| Jun | 10 | 4 of 10 | +12% |
| Jul | 11 | 6 of 11 | +1.1% |
| Aug | 11 | 5 of 11 | +1.6% |
| Sep | 11 | 5 of 11 | +6.0% |
| Oct | 11 | 3 of 11 | −11% |
| Nov | 10 | 6 of 10 | +9.9% |
| Dec | 10 | 5 of 10 | −3.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.